CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. JNCE (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC (“Concentra”), through its wholly owned subsidiary Concentra Merger Sub, Inc. (“Concentra Merger…Read More
Jounce Therapeutics Announces Closing of Tender Offer Jounce Therapeutics NASDAQJNCE
